Outcomes of AML patients with wild-type NPM1 based on the presence of a PTPN11 mutation
| End point . | PTPN11mut . | PTPN11wt . | P* . |
|---|---|---|---|
| (n = 38) . | (n = 703) . | ||
| Younger patients (age <60 y) | |||
| Early death, n (%) | 3 (8) | 33 (5) | .42 |
| CR, n (%) | 17 (45) | 498 (71) | .002 |
| DFS | .96 | ||
| Median, y | 2.2 | 1.2 | |
| % Disease free at 1 y (95% CI) | 65 (38-82) | 55 (51-60) | |
| % Disease free at 3 y (95% CI) | 29 (11-51) | 38 (33-42) | |
| OS | .04 | ||
| Median, y | 0.8 | 1.8 | |
| % Alive at 1 y (95% CI) | 46 (30-61) | 67 (63-70) | |
| % Alive at 3 y (95% CI) | 30 (16-45) | 41 (38-45) | |
| EFS | .008 | ||
| Median, y | 0.2 | 0.8 | |
| % Event-free at 1 y (95% CI) | 29 (16-44) | 41 (37-45) | |
| % Event-free at 3 y (95% CI) | 13 (5-26) | 27 (24-30) |
| End point . | PTPN11mut . | PTPN11wt . | P* . |
|---|---|---|---|
| (n = 38) . | (n = 703) . | ||
| Younger patients (age <60 y) | |||
| Early death, n (%) | 3 (8) | 33 (5) | .42 |
| CR, n (%) | 17 (45) | 498 (71) | .002 |
| DFS | .96 | ||
| Median, y | 2.2 | 1.2 | |
| % Disease free at 1 y (95% CI) | 65 (38-82) | 55 (51-60) | |
| % Disease free at 3 y (95% CI) | 29 (11-51) | 38 (33-42) | |
| OS | .04 | ||
| Median, y | 0.8 | 1.8 | |
| % Alive at 1 y (95% CI) | 46 (30-61) | 67 (63-70) | |
| % Alive at 3 y (95% CI) | 30 (16-45) | 41 (38-45) | |
| EFS | .008 | ||
| Median, y | 0.2 | 0.8 | |
| % Event-free at 1 y (95% CI) | 29 (16-44) | 41 (37-45) | |
| % Event-free at 3 y (95% CI) | 13 (5-26) | 27 (24-30) |
| End point . | PTPN11mut . | PTPN11wt . | P* . |
|---|---|---|---|
| (n = 17) . | (n = 371) . | ||
| Older patients (age ≥60 y) | |||
| Early death, n (%) | 2 (12) | 60 (16) | 1.00 |
| CR, n (%) | 3 (18) | 159 (43) | .04 |
| DFS | .02 | ||
| Median, y | 0.3 | 0.6 | |
| % Disease-free at 1 y (95% CI) | 0 | 34 (27-42) | |
| % Disease-free at 3 y (95% CI) | 0 | 10 (6-15) | |
| OS | .58 | ||
| Median, y | 0.4 | 0.6 | |
| % Alive at 1 y (95% CI) | 24 (7-45) | 32 (27-37) | |
| % Alive at 3 y (95% CI) | 12 (2-31) | 10 (7-13) | |
| EFS | .02 | ||
| Median, y | 0.2 | 0.2 | |
| % Event-free at 1 y (95% CI) | 0 | 18 (14-22) | |
| % Event-free at 3 y (95% CI) | 0 | 4 (3-7) |
| End point . | PTPN11mut . | PTPN11wt . | P* . |
|---|---|---|---|
| (n = 17) . | (n = 371) . | ||
| Older patients (age ≥60 y) | |||
| Early death, n (%) | 2 (12) | 60 (16) | 1.00 |
| CR, n (%) | 3 (18) | 159 (43) | .04 |
| DFS | .02 | ||
| Median, y | 0.3 | 0.6 | |
| % Disease-free at 1 y (95% CI) | 0 | 34 (27-42) | |
| % Disease-free at 3 y (95% CI) | 0 | 10 (6-15) | |
| OS | .58 | ||
| Median, y | 0.4 | 0.6 | |
| % Alive at 1 y (95% CI) | 24 (7-45) | 32 (27-37) | |
| % Alive at 3 y (95% CI) | 12 (2-31) | 10 (7-13) | |
| EFS | .02 | ||
| Median, y | 0.2 | 0.2 | |
| % Event-free at 1 y (95% CI) | 0 | 18 (14-22) | |
| % Event-free at 3 y (95% CI) | 0 | 4 (3-7) |
CI, confidence interval.
P values are from Fisher’s exact test for early death and CR and from the log-rank test for DFS, OS, and EFS.